News
Ashley McBryde named her guitar Dinah because she played her a lot in the kitchen. Read where Eddie Van Halen's "Frankenstein" guitar ended up after his death. Willie Nelson has been playing his ...
The guitar Michael J. Fox played in "Back to the Future" has long been missing. A new documentary and Nashville's Gibson Guitars hope to change that.
Now comes the bittersweet part: You can't buy these guitars. Instead, Xbox will be giving them away via its Instagram accounts, with residents from the US, Canada, the UK, France, Germany, Austria ...
The Novo Sonidos Orchestra summer music camp program, a five-week session scheduled from mid-June through late July, continues into its fourth year under the directorship of Quintin Leger at the West ...
Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Danish pharmaceutical giant Novo Nordisk is saying goodbye to its chief executive amid growing competition for its blockbuster weight loss drugs Wegovy and Ozempic. Lars Fruergaard Jørgensen, who ...
It’s the end of an era at Novo as longtime CEO Lars Fruergaard Jørgensen—who shepherded the company through its GLP-1 growth boom—heads for the exit.
Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased competition for its ...
Novo Nordisk’s semaglutide drug is in a class of drugs known as GLP-1 agonists, which simulate a hormone that would naturally be released during digestion. Its drug, marketed as Ozempic, was ...
Novo reported $11.9 billion in revenue, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) with $0.99 per share compared to estimates of $0.94 per share.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results